GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (BOM:524774) » Definitions » Debt-to-EBITDA

NGL Fine-Chem (BOM:524774) Debt-to-EBITDA : 0.74 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is NGL Fine-Chem Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NGL Fine-Chem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹296 Mil. NGL Fine-Chem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹196 Mil. NGL Fine-Chem's annualized EBITDA for the quarter that ended in Sep. 2024 was ₹667 Mil. NGL Fine-Chem's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.74.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NGL Fine-Chem's Debt-to-EBITDA or its related term are showing as below:

BOM:524774' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19   Med: 0.71   Max: 1.26
Current: 0.71

During the past 13 years, the highest Debt-to-EBITDA Ratio of NGL Fine-Chem was 1.26. The lowest was 0.19. And the median was 0.71.

BOM:524774's Debt-to-EBITDA is ranked better than
66.62% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs BOM:524774: 0.71

NGL Fine-Chem Debt-to-EBITDA Historical Data

The historical data trend for NGL Fine-Chem's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGL Fine-Chem Debt-to-EBITDA Chart

NGL Fine-Chem Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 0.19 0.38 0.82 0.51

NGL Fine-Chem Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 - 0.44 - 0.74

Competitive Comparison of NGL Fine-Chem's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's Debt-to-EBITDA falls into.



NGL Fine-Chem Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NGL Fine-Chem's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(332.59 + 7.448) / 673.969
=0.50

NGL Fine-Chem's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(296.008 + 196.021) / 666.928
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


NGL Fine-Chem  (BOM:524774) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NGL Fine-Chem Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NGL Fine-Chem's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NGL Fine-Chem Business Description

Traded in Other Exchanges
Address
301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. The company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its product includes Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and Finished dosage form, of which maximum revenue is generated from Veterinary APIs. Its geographical segments include India, Europe, Asia Pacific, United States, and Rest of the world. The Group's business activities fall within a single business segment of pharmaceuticals.

NGL Fine-Chem Headlines

No Headlines